Pick a protocol → confirm logistics → review what gets created.
28-day cycle, doses on D1, D8, D15. D22 is rest. First-line standard for mPDAC.
28-day cycle, doses D1 and D15 only. Dose-sparing schedule for function preservation.
Weekly 3-on 1-off after response plateau. Lower toxicity than GnP; preserves function.
14-day cycle. Day 1 infusion + 46h 5-FU pump. Higher response rate but more toxicity than GnP.
28-day GnP backbone (D1/D8/D15 infusions) plus continuous oral narmafotinib (AMP945) — an investigational FAK inhibitor studied in the ACCENT trial in mPDAC (NCT05355298). Hypothesis: disrupting stromal fibrosis improves chemo delivery. Standard GnP backbone monitoring (FBC, LFTs, U&Es D1/D8/D15) applies; oral adherence is critical.